Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers for advanced non-small-cell lung cancer treated with immunotherapy: a …
Background and Objectives: Advanced non-small-cell lung cancer (NSCLC) has led to a
high number of mortalities. Immunotherapy, as a first-line treatment in advanced NSCLC …
high number of mortalities. Immunotherapy, as a first-line treatment in advanced NSCLC …
Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and …
W Zhang, Y Tan, Y Li, J Liu - Frontiers in Immunology, 2023 - frontiersin.org
Background The use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an
increase in immune-related adverse events (irAEs), which can cause treatment …
increase in immune-related adverse events (irAEs), which can cause treatment …
Mechanisms of immune checkpoint inhibitor-mediated colitis
H Westdorp, MWD Sweep, MAJ Gorris… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several
cancer types. However, systemic activation of the immune system also leads to several …
cancer types. However, systemic activation of the immune system also leads to several …
Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer
X Lin, H Deng, Y Yang, J Wu, G Qiu, S Li, X Xie… - Frontiers in …, 2021 - frontiersin.org
Background Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-
related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs) …
related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs) …
Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review …
K Zhou, J Cao, H Lin, L Liang, Z Shen, L Wang… - Frontiers in …, 2022 - frontiersin.org
Background It remains controversial whether the platelet to lymphocyte ratio (PLR) serves as
a potential indicator for the efficacy of immunotherapy in advanced lung cancer. This meta …
a potential indicator for the efficacy of immunotherapy in advanced lung cancer. This meta …
[HTML][HTML] Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer
Introduction Pembrolizumab is an established first-line option for patients with advanced non-
small-cell lung cancer (NSCLC) expressing programmed death-ligand 1≥ 50%. Durable …
small-cell lung cancer (NSCLC) expressing programmed death-ligand 1≥ 50%. Durable …
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
J Ancel, V Dormoy, BN Raby, V Dalstein… - Frontiers in …, 2023 - frontiersin.org
Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …
Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-Lymphocyte …
A Bongiovanni, F Foca, J Menis, SL Stucci… - Frontiers in …, 2021 - frontiersin.org
Introduction Bone metastases (BMs) are a negative prognostic factor in patients with non-
small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs) have …
small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs) have …
Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis
H Wang, C Li, R Yang, J Jin, D Liu, W Li - PloS one, 2022 - journals.plos.org
Background Current studies have revealed that the platelet to lymphocyte ratio (PLR) may
lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a …
lead to a poor prognosis in lung cancer patients receiving immunotherapy. We conducted a …
[HTML][HTML] Neutrophil-to-lymphocyte ratio is a major prognostic factor in non-small cell lung carcinoma patients undergoing first line immunotherapy with pembrolizumab
FJ Romano, R Ronga, F Ambrosio… - Cancer diagnosis & …, 2023 - ncbi.nlm.nih.gov
Background/Aim: Lung cancer is one of the most common malignant neoplastic diseases
and by far the leading cause of cancer death worldwide. Recently, immune checkpoint …
and by far the leading cause of cancer death worldwide. Recently, immune checkpoint …